Voices
Hidehito Horinouchi: New Combination Strategy in SCLC After First Line Chemoimmunotherapy
Hidehito Horinouchi/X

Hidehito Horinouchi: New Combination Strategy in SCLC After First Line Chemoimmunotherapy

Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:

“Oral Abstract Session.

Ivonescimab Plus Liposomal Irinotecan in SCLC Progressing after First-Line Chemoimmunotherapy

  • Dr. Yun Fan
  • 8007
  • NCT06478043.”

Read more.

Hidehito Horinouchi: New Combination Strategy in SCLC After First Line Chemoimmunotherapy

ASCO 2026 Lung Cancer Preview: Key Trials With Practice-Changing Potential
Hidehito Horinouchi: New Combination Strategy in SCLC After First Line Chemoimmunotherapy

cancer Hidehito Horinouchi Lung cancer OncoDaily Oncology Yun Fan